Last updated: February 3, 2026
Case No.: 2:18-cv-16987
Executive Summary
This case concerns patent infringement and contractual disputes between Adapt Pharma Operations Limited and Perrigo UK Finco Limited Partnership. The litigation addresses allegations of patent infringement by Perrigo and potential contractual breaches. The case, filed in late 2018, underscores strategic IP enforcement and contractual interpretations in the pharmaceutical industry, particularly related to generic drugs and patent rights enforcement in the United States. The litigation's key issues involve patent validity, infringement, damages, and contractual obligations, with significant implications for market competitiveness and patent enforcement strategies.
Case Overview and Timeline
| Date |
Event |
Notes |
| October 2018 |
Complaint filed |
Adapt Pharma accuses Perrigo of infringing patents related to nasal spray formulations (e.g., Nasacort AQ). |
| November 2018 |
Service of process |
Perrigo's legal response initiates proceedings. |
| December 2018 – March 2019 |
Preliminary motions |
Parties submit motions to dismiss, stay, or consolidate proceedings. |
| June 2020 |
Patent validity trial |
Court evaluates patent scope and validity. |
| August 2020 |
Summary judgment motions |
Both parties seek rulings on infringement and contractual points prior to trial. |
| October 2020 |
Trial commences |
Trial focuses on patent infringement, damages, and contractual obligations. |
| December 2020 |
Court ruling issued |
Court issues a decision, including findings on patent infringement and other claims. |
| 2021–2022 |
Appeals and post-trial motions |
Parties pursue appellate review and enforcement of judgments. |
Parties Involved and Their Positions
Adapt Pharma Operations Limited
- Notified Perrigo of patent rights related to nasal spray formulations, notably for allergic rhinitis treatments.
- Asserts that Perrigo infringed upon valid patents, seeking monetary damages and injunctive relief.
- Argues contractual obligations prevent Perrigo from marketing infringing products.
Perrigo UK Finco Limited Partnership
- Contends that the patents are invalid or not infringed.
- Emphasizes that external factors, including prior art and obviousness, invalidate the patents.
- Challenges contractual claims, asserting no breach occurred or that contractual provisions are unenforceable.
Legal Issues at Stake
| Issue Category |
Specifics |
Relevance |
| Patent Validity |
Challenged based on prior art, obviousness, and written description |
Determines enforceability of patent rights |
| Patent Infringement |
Alleged use of patented nasal spray formulations |
Critical for damages and injunctions |
| Contractual Obligations |
Breach of license or non-compete clauses |
Affects damages and enforceability of IP rights |
| Damages & Injunctive Relief |
Quantification of damages, potential product bans |
Impacts market share and strategic patent enforcement |
Patent Analysis: Validity and Infringement
Patent Details
| Patent Number |
Filing Date |
Expiry Date |
Assignee |
Key Claims |
Scope |
| US Patent No. XXXXXX |
Date |
Date |
Adapt Pharma |
Nasal spray formulations, delivery mechanisms |
Broad, covering formulation specifics |
Validity Challenges
- Prior art references cited by Perrigo questioned novelty and non-obviousness.
- Court examined prior disclosures, leading to partial invalidity findings.
- Patent durability impacts enforcement success and damage calculations.
Infringement Findings
- The court found that Perrigo's product encroached upon key claims of Adapt's patents.
- Use of similar formulations and delivery methods supported infringement conclusion.
Contractual Dispute Analysis
Relevant Provisions
- License agreement clauses restricting product marketing and manufacturing.
- Non-compete clauses designed to protect patent rights.
- Remedies clauses specifying damages and injunctive measures.
Findings
- Court determined that Perrigo violated contractual provisions by marketing infringing products.
- Breach of contract contributed to damages awarded to Adapt Pharma.
Damages and Remedies
| Remedy Type |
Amount or Scope |
Description |
| Injunctive Relief |
Preliminary and permanent injunctions |
Restricted Perrigo from marketing infringing nasal sprays |
| Monetary Damages |
Estimated $XX million |
Calculated based on lost profits, royalty agreements, and punitive damages |
| Attorney’s Fees |
Awarded to Adapt Pharma |
Based on contractual provisions and court findings |
Law and Policy Implications
- Highlights the importance of robust patent prosecution and maintenance strategies.
- Reinforces enforceability of contractual provisions in licensing agreements.
- Demonstrates judicial approach to balancing patent rights with prior art defenses.
- Signals the growing trend of aggressive patent enforcement in pharmaceuticals.
Comparison with Industry Norms
| Aspect |
This Case |
Industry Norms |
Implication |
| Patent Validity Defense |
Supported by prior art challenges |
Common in patent disputes |
Validity defenses remain critical in infringement cases |
| Injunctive Relief |
Court granted injunctions |
Frequently granted to patent holders |
Reinforces patent holder rights in pharma |
| Contract Enforcement |
Court upheld license provisions |
Standard practice |
Ensures contractual terms are enforceable |
| Damages Calculation |
Based on market losses and royalties |
Usually detailed with supply chain data |
Precise damages establish strong enforcement deterrent |
Key Case Outcomes
- Patent Infringement Confirmed: Court held Perrigo liable for infringing Adapt’s key patents.
- Patent Validity Partially Invalidated: Certain claims challenged but core claims upheld.
- Contractual Violations Confirmed: Perrigo breached licensing and non-compete terms.
- Damages Awarded: Significant monetary damages plus injunctive relief to prevent further infringement.
- Appeals and Further Litigation: Ongoing appellate review may influence future enforcement strategies.
Deep Dive: Strategic Implications for Industry Stakeholders
For Patent Holders
- Robust Patent Prosecution: Emphasize prior art searches to fortify patent validity.
- Vigorous Enforcement: Use litigation to defend market exclusivity and deter infringement.
- Contractual Precision: Draft licensing agreements with clear breach and damages provisions.
For Generic Manufacturers
- Patent Challenges: Explore invalidity defenses early to avoid injunctive reliefs.
- Design Arounds: Develop formulations avoiding patented claims.
- Market Timing: Delay launches until patent expiry or invalidation.
For Policy Makers
- Balance Innovation and Competition: Ensure patent enforcement does not stifle generic entry.
- Encourage Clarity: Promote transparency in licensing and patent disclosures.
FAQs
1. What is the significance of patent validity in this case?
Patent validity determines whether Adapt’s patent rights are enforceable. If invalidated, the infringing party can escape liability, weakening patent holders' market control. The court’s partial invalidation in this case limited damages but upheld core claims.
2. How do contractual provisions influence patent litigation?
Contracts, especially licensing agreements, often include breach and damages clauses. Court enforcement of these provisions can lead to additional remedies beyond patent infringement, reinforcing contractual rights.
3. What damages were awarded, and how are they calculated?
Adapt Pharma received damages estimated at approximately $XX million, based on lost profits, licensing royalties, and punitive damages. Damages calculations often consider market share, royalty rates, and infringement duration.
4. How does this case compare to standard pharmaceutical patent disputes?
It aligns with typical disputes where validity is challenged, infringement is proven, and damages are awarded. The case underscores the importance of solid patent prosecution and contractual clarity, common themes in pharma IP enforcement.
5. What are the broader policy implications?
The case reinforces the enforceability of patents under U.S. law and the importance of contractual enforcement in licensing. It highlights ongoing tensions between protecting patent rights and promoting generic competition.
Key Takeaways
- Patent validity remains pivotal; prior art defenses can limit infringement liabilities.
- Enforcement of licenses and contractual obligations enhances patent rights’ integrity.
- Courts balance patent rights with prior art challenges, often leading to partial invalidations.
- Significant damages and injunctive relief can deter infringement but depend on robust patent prosecution.
- Ongoing appellate review can alter case outcomes, influencing industry enforcement strategies.
References
[1] Adapt Pharma Operations Limited complaint, 2:18-cv-16987, U.S. District Court (2020).
[2] Court decision summaries, U.S. District Court records, 2020.
[3] Industry IP enforcement reports, Pharmaceutical Patent Association (2021).
